Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

NCT04132505 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

DRUG: Binimetinib
DRUG: Hydroxychloroquine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]